CREATE Medicines
createmedicines.com
Actively hiring
Vaccines
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Backers
2
8VC, ARCH Venture Partners
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
Backed byfrom the funds' portfolios and accelerator catalogs
ARCH Venture Partners Similar startupsby what they do, their industry and backers
Positioned to deliver revolutionary off-the-shelf cancer vaccines. OUR CORE MISSION.
Learn about BLINCYTO® (blinatumomab), a treatment for adults and children with CD-19 positive B-cell precursor acute lymphoblastic leukemia…
TareBio develops vaccines for cancer and infectious diseases by decoding immune responses to engineer targeted antigens.
Gamgee is developing personalised mRNA vaccines as a cancer treatment for dogs, built from each dog’s tumour. See how it works with vets…
Zoetis is a global animal health company dedicated to supporting customers and their businesses in ever better ways. Building on 60 years…
Protecting against viral threats. Ushering in a new era of AI-enabled vaccine design.
News
CREATE Medicines Expands Clinical In Vivo CAR Pipeline and LNP Technology Suite by Forming Strategic Collaboration With WestGene
Read more
Report
CREATE Medicines expands targeted in vivo CAR platform through strategic research collaboration and exclusive license pact with Monash University
CREATE Medicines expands targeted in vivo CAR platform through strategic research collaboration and exclusive license pact with Monash University
Read more
Report
CREATE Medicines Receives Approval to Initiate First-in-Human Phase 1/2 Clinical Trial of In Vivo CAR-T Candidate CRT-402 for Autoimmune Diseases
Read more
Report
Financing at Create Medicines to advance in vivo CAR therapies
Create Medicines Inc. has closed a $122 million series B funding round to support progression of its pipeline of in vivo CAR therapies across autoimmune disease and oncology. The company's proprietary mRNA-LNP platform directly engineers T cells, NK cells
Read more
Report
CREATE Medicines Announces $122 Million Series B Financing to Advance In Vivo CAR Pipeline in Autoimmune Disease and Oncology
CREATE Medicines, Inc. ("CREATE"), a clinical-stage biotechnology company pioneering in vivo immune programming, today announced the closing of its $122 million Series B funding round, co-led by existing investors Newpath Partners, ARCH Venture Partners,
Read more
Report
Pro access
Upgrade to see all 6 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Cambridge
United States
Regional office
300 Technology Square, Suite 203, Cambridge, MA, 02139, US